Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24


Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.

Ferris RL, Saba NF, Gitlitz BJ, Haddad R, Sukari A, Neupane P, Morris JC, Misiukiewicz K, Bauman JE, Fenton M, Jimeno A, Adkins DR, Schneider CJ, Sacco AG, Shirai K, Bowles DW, Gibson M, Nwizu T, Gottardo R, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Cohen EEW.

JAMA Oncol. 2018 Jun 21. doi: 10.1001/jamaoncol.2018.1888. [Epub ahead of print]


Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.

Chow LQM, Morishima C, Eaton KD, Baik CS, Goulart BH, Anderson LN, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Disis ML, Martins RG.

Clin Cancer Res. 2017 May 15;23(10):2442-2450. doi: 10.1158/1078-0432.CCR-16-1934. Epub 2016 Nov 3.


Motolimod effectively drives immune activation in advanced cancer patients.

Dietsch GN.

Oncoimmunology. 2016 Feb 9;5(5):e1126037. doi: 10.1080/2162402X.2015.1126037. eCollection 2016 May.


VTX-1463, a novel TLR-8 agonist, attenuates nasal congestion after ragweed challenge in sensitized beagle dogs.

Royer CM, Rudolph K, Dietsch GN, Hershberg RM, Barrett EG.

Immun Inflamm Dis. 2015 Dec 7;4(1):45-51. doi: 10.1002/iid3.91. eCollection 2016 Mar.


Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity.

Dietsch GN, Lu H, Yang Y, Morishima C, Chow LQ, Disis ML, Hershberg RM.

PLoS One. 2016 Feb 29;11(2):e0148764. doi: 10.1371/journal.pone.0148764. eCollection 2016.


Toll-like Receptor 4 Ligands Down-regulate Fcγ Receptor IIb (FcγRIIb) via MARCH3 Protein-mediated Ubiquitination.

Fatehchand K, Ren L, Elavazhagan S, Fang H, Mo X, Vasilakos JP, Dietsch GN, Hershberg RM, Tridandapani S, Butchar JP.

J Biol Chem. 2016 Feb 19;291(8):3895-904. doi: 10.1074/jbc.M115.701151. Epub 2015 Dec 22.


Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337).

Dietsch GN, Randall TD, Gottardo R, Northfelt DW, Ramanathan RK, Cohen PA, Manjarrez KL, Newkirk M, Bryan JK, Hershberg RM.

Clin Cancer Res. 2015 Dec 15;21(24):5445-52. doi: 10.1158/1078-0432.CCR-15-0578. Epub 2015 Jul 7.


Granzyme B expression is enhanced in human monocytes by TLR8 agonists and contributes to antibody-dependent cellular cytotoxicity.

Elavazhagan S, Fatehchand K, Santhanam V, Fang H, Ren L, Gautam S, Reader B, Mo X, Cheney C, Briercheck E, Vasilakos JP, Dietsch GN, Hershberg RM, Caligiuri M, Byrd JC, Butchar JP, Tridandapani S.

J Immunol. 2015 Mar 15;194(6):2786-95. doi: 10.4049/jimmunol.1402316. Epub 2015 Feb 9.


A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma.

Northfelt DW, Ramanathan RK, Cohen PA, Von Hoff DD, Weiss GJ, Dietsch GN, Manjarrez KL, Randall TD, Hershberg RM.

Clin Cancer Res. 2014 Jul 15;20(14):3683-91. doi: 10.1158/1078-0432.CCR-14-0392. Epub 2014 May 7.


The ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes.

Dowling DJ, Tan Z, Prokopowicz ZM, Palmer CD, Matthews MA, Dietsch GN, Hershberg RM, Levy O.

PLoS One. 2013;8(3):e58164. doi: 10.1371/journal.pone.0058164. Epub 2013 Mar 4.


VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC.

Lu H, Dietsch GN, Matthews MA, Yang Y, Ghanekar S, Inokuma M, Suni M, Maino VC, Henderson KE, Howbert JJ, Disis ML, Hershberg RM.

Clin Cancer Res. 2012 Jan 15;18(2):499-509. doi: 10.1158/1078-0432.CCR-11-1625. Epub 2011 Nov 29.


Characterization of the inflammatory response to a highly selective PDE4 inhibitor in the rat and the identification of biomarkers that correlate with toxicity.

Dietsch GN, Dipalma CR, Eyre RJ, Pham TQ, Poole KM, Pefaur NB, Welch WD, Trueblood E, Kerns WD, Kanaly ST.

Toxicol Pathol. 2006;34(1):39-51.


Prevention of vasospasm by anti-CD11/CD18 monoclonal antibody therapy following subarachnoid hemorrhage in rabbits.

Pradilla G, Wang PP, Legnani FG, Ogata L, Dietsch GN, Tamargo RJ.

J Neurosurg. 2004 Jul;101(1):88-92.


Prevention of cerebral vasospasm by a humanized anti-CD11/CD18 monoclonal antibody administered after experimental subarachnoid hemorrhage in nonhuman primates.

Clatterbuck RE, Gailloud P, Ogata L, Gebremariam A, Dietsch GN, Murphy KJ, Tamargo RJ.

J Neurosurg. 2003 Aug;99(2):376-82.


Inhibition of vasospasm with lymphocyte function-associated antigen-1 monoclonal antibody in a femoral artery model in rats.

Clatterbuck RE, Oshiro EM, Hoffman PA, Dietsch GN, Pardoll DM, Tamargo RJ.

J Neurosurg. 2002 Sep;97(3):676-82.


Requirements for alpha d in IgG immune complex-induced rat lung injury.

Shanley TP, Warner RL, Crouch LD, Dietsch GN, Clark DL, O'Brien MM, Gallatin WM, Ward PA.

J Immunol. 1998 Jan 15;160(2):1014-20.


The role of recombinant platelet-activating factor acetylhydrolase in a neonatal rat model of necrotizing enterocolitis.

Caplan MS, Lickerman M, Adler L, Dietsch GN, Yu A.

Pediatr Res. 1997 Dec;42(6):779-83.


Inhibition of experimental vasospasm with anti-intercellular adhesion molecule-1 monoclonal antibody in rats.

Oshiro EM, Hoffman PA, Dietsch GN, Watts MC, Pardoll DM, Tamargo RJ.

Stroke. 1997 Oct;28(10):2031-7; discussion 2037-8.


Chemokine expression in murine experimental allergic encephalomyelitis.

Godiska R, Chantry D, Dietsch GN, Gray PW.

J Neuroimmunol. 1995 May;58(2):167-76.


Mast cell proteases liberate stable encephalitogenic fragments from intact myelin.

Dietsch GN, Hinrichs DJ.

Cell Immunol. 1991 Jul;135(2):541-8.


The role of mast cells in the elicitation of experimental allergic encephalomyelitis.

Dietsch GN, Hinrichs DJ.

J Immunol. 1989 Mar 1;142(5):1476-81.


Supplemental Content

Loading ...
Support Center